Physician profile
John W Xerogeanes
NPI 1346342045
$4,016,654.29
in general payments reported to CMS, 2019-2025
4 companies · $686K in 2025
The $686K reported for 2025 was more than what 99% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $161K · 2021: $375K · 2022: $767K · 2023: $1.1M · 2024: $905K · 2025: $686K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $2.6M · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $23K · Travel and Lodging: $4,117 · Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $2,582,311.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,950.07 |
| Consulting Fee | $22,525.54 |
| Travel and Lodging | $4,116.50 |
| Food and Beverage | $957.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $4,004,228.12 | 2019-2025 | Arthrex, Knee & Hip Implants Suspensory Fixation Acl Tightrope |
| Trice Medical, INC. | $8,768.45 | 2019-2025 | |
| United Orthopedics LLC | $3,657.72 | 2020-2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,044.11 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Xerogeanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.